Department of Genetics & Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Pharmacogenomics. 2022 Jul;23(10):597-607. doi: 10.2217/pgs-2022-0037. Epub 2022 Jun 8.
Antidepressant medications are frequently used as the first line of treatment for depression. However, their effectiveness is highly variable and influenced by genetic factors. Recently, pharmacogenetic studies, including candidate-gene, genome-wide association studies or polygenic risk scores, have attempted to uncover the genetic architecture of antidepressant response. Genetic variants in at least 27 genes are linked to antidepressant treatment response in both coding and non-coding genomic regions, but evidence is largely inconclusive due to the high polygenicity of the trait and limited cohort sizes in published studies. Future studies should increase the number and diversity of participants to yield sufficient statistical power to characterize the genetic underpinnings and biological mechanisms of treatment response, improve results generalizability and reduce racial health-related inequities.
抗抑郁药物常被用作治疗抑郁症的一线药物。然而，它们的疗效具有高度可变性，并受遗传因素的影响。最近，药物遗传学研究，包括候选基因、全基因组关联研究或多基因风险评分，试图揭示抗抑郁反应的遗传结构。编码和非编码基因组区域中至少有 27 个基因的遗传变异与抗抑郁治疗反应相关，但由于该特征的高度多基因性和已发表研究中的队列规模有限，证据大多不明确。未来的研究应增加参与者的数量和多样性，以获得足够的统计能力来描述治疗反应的遗传基础和生物学机制，提高结果的可推广性，并减少与种族有关的健康不平等。
